Category: Pharma, Life Sciences & Med Tech Players
-
Teva removes more than 200 patents from U.S. FDA’s Orange Book: win for FTC
Following President Trump’s promise to lower the cost of drugs and a United States Federal Trade Commission investigation into a patent portfolio owned by Teva, the Israeli pharma company has asked the Food and Drug Administration to remove more than 200 improper patent listings related to asthma, diabetes, and COPD drugs, and epinephrine autoinjectors, from…
-
Some direct patent infringement “acceptable price” for expediting competition: U.S. Solicitor General urges Supreme Court to review skinny labeling and generic drug access
United States Solicitor General D. John Sauer has filed a petition urging the Supreme Court to intervene in a long-running drug patent infringement case in which he alleges the Federal Circuit failed to apply the “skinny labelling” (section viii) pathway, which allows the entry of generics that carve out patented uses but otherwise duplicate the…
-
UPC’s Roche-Menarini preliminary injunction clarifies relationship between independent product and manufacturing method claims
An independent method claim cannot, without more, result in further requirements for the infringement of an independent product claim.
-
10x Genomics, Moderna, Novo Nordisk among newly confirmed speakers for Patent Litigation Europe event (pharma & tech) next month
Eric Whitaker, Chief Legal Officer at 10x Genomics, Karen Guo, Senior Director of Patents & IP at Novo Nordisk, and Katherine Hinterberg, Senior Director of Patent Litigation at Moderna, will speak at Kisaco Research’s annual Pharma and Biotech Patent Litigation Europe in Amsterdam.
-
Halozyme wins Munich PI against Merck’s Keytruda SC (subcutaneous immunotherapy); meanwhile, litigators await appointment of Judge Werner’s successor
On Thursday, Halozyme obtained a preliminary injunction against Merck’s Keytruda SC.
-
Delhi High Court allows Dr. Reddy’s to enter Indian semaglutide market in March 2026, dismisses Novo Nordisk appeal
In a landmark judgment, the Delhi High Court has ruled that Novo Nordisk failed to prove why it should be granted an interim injunction against Dr. Reddy’s, but has ordered the latter not to proceed with sales in Indian until the patent-in-suit expires on March 20, 2026.
-
Federal Circuit tosses Pfizer’s $42M+8% verdict against Daiichi, AstraZeneca: claiming 81 combinations out of gazillions described defeats disclosure, enablement
In a precedential opinion, the central U.S. appeals court for patent rulings overturns a Texas jury verdict given the discrepancy between a broad description and a specific claim term.
-
Next UPC CoA landmark ruling: pragmatic on inventive-step standard; focused on when amendments could be presented; tough but fair on remedies (Edwards v. Meril)
Another major UPC appellate ruling came down on Tuesday, and it provides a variety of clarifications of transcendental importance.
-
UPC CoA reverses invalidation of Amgen patent, clarifies standards for added matter and sufficient disclosure; infringement action to resume
In a high-stakes life sciences case, the UPC’s CoA has provided its most far-reaching clarifications on (in)validity to date.
-
Boehringer wins PI against Dr. Reddy’s that blocks generic empagliflozin (Jardiance) sales in UK pending October 2026 trial: patent thickets work
In some jurisdictions it pays off for Boehringer Ingelheim to have created a patent thicket around empaglifozin (Jardiance) involving use and formulation patents.